Understand the source comparison
Best Peptides for Stubborn Belly Fat: Mechanism Comparison
Survodutide (GLP-1/Glucagon) Incretin receptor agonism + hepatic fat oxidation High. Glucagon receptors densely expressed in visceral adipocytes 15.7% body weight reduction, 18.2% visceral fat reduction (Phase 2, The Lancet) ~5 days Most robust clinical eviden
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Survodutide (GLP-1/Glucagon)
- Incretin receptor agonism + hepatic fat oxidation
- High. Glucagon receptors densely expressed in visceral adipocytes
- 15.7% body weight reduction, 18.2% visceral fat reduction (Phase 2, The Lancet)
- ~5 days
- Most robust clinical evidence for visceral fat reduction specifically; dual mechanism addresses both intake and oxidation
- Mazdutide (GLP-1/Glucagon)
- Dual incretin + glucagon agonism
- High. Similar mechanism to survodutide
- 22% visceral fat reduction in rodent models; human trials ongoing
- 6–7 days
- Longer half-life reduces gastric side effects; less clinical data than survodutide but mechanism suggests similar efficacy
- CJC-1295/Ipamorelin
- Growth hormone secretagogue (pulsatile release)
- Moderate. GH preferentially mobilizes visceral fat via HSL upregulation
- 19% visceral fat reduction in aged rodent models over 90 days
- CJC: 6–8 days; Ipa: 2 hours
- Avoids IGF-1 spikes of exogenous GH; combination maintains physiological pulsatile pattern
- MK-677 (Ibutamoren)
- Ghrelin mimetic (oral GH secretagogue)
- Moderate. Beta-3 adrenergic receptor density drives selectivity
- 8–12% BMR increase; fat loss effect offset by appetite stimulation in free-feeding models
- 24 hours
- Oral bioavailability is convenient; appetite increase requires dietary control to realize fat loss benefit
- Tesofensine
- Triple monoamine reuptake inhibitor (NE/5-HT/DA)
- Moderate-High. Norepinephrine activates beta-3 receptors preferentially in visceral fat
- 12.8% body weight reduction over 24 weeks (Phase 2, The Lancet)
- 6–8 days
- Strongest single-agent weight loss data; cardiovascular side effects (elevated HR/BP) require monitoring
- SLU-PP-332
- ERRα/γ agonist (mitochondrial biogenesis, PGC-1α upregulation)
- High. Visceral adipocytes have higher mitochondrial density
- 12% body fat reduction in rodents over 28 days; no appetite suppression
- ~18 hours
- Pure metabolic mechanism; no caloric restriction required; early-stage research compound